Skip to main content
AAPL+0.64%MSFT+1.07%NVDA+0.64%GOOGL+0.80%AMZN+1.46%SPCX+1.27%TSM+0.81%AVGO+3.64%META+0.81%TSLA+0.74%LLY-2.33%WMT-0.13%AMD+5.31%SKHY-0.11%JPM-1.77%BRK-B-2.07%MU+1.55%V-0.37%JNJ-2.15%XOM-3.97%MA-0.37%ASMLa+1.94%ABBV-2.33%COST-1.21%1398.HK-0.79%0700.HK-5.82%KO-0.71%CVX-4.74%PG-0.83%CSCO+2.18%0939.HK-0.24%ORCL-0.97%3988.HK-0.36%GE+0.52%BAC-1.07%HD-0.40%1816.HK-26.17%0857.HK-2.43%UNH-10.21%1288.HK-1.64%PM-0.85%0005.HK-2.03%NVS-2.46%HSBA.L-2.00%INTC-0.91%MS-1.29%AMAT+0.88%AP2d+2.23%AZN-1.93%TXN-1.16%AUDJPY-1.58%AUDUSD-1.47%EURAUD+0.95%AUDCAD-0.92%AUDCHF-0.90%GBPAUD+0.88%AUDNZD-0.88%NZDJPY-0.72%GBPJPY-0.70%CHFJPY-0.68%CADJPY-0.67%EURJPY-0.65%USDCHF+0.60%NZDUSD-0.59%GBPUSD-0.57%USDCAD+0.57%AUDSGD-0.56%EURUSD-0.52%AUDDKK-0.51%GBPTRY+0.41%AUDNOK-0.40%USDZAR+0.33%GBPHKD+0.32%NZDMXN+0.32%USDMXN+0.32%USDTHB+0.30%GBPMXN-0.28%EURZAR+0.24%GBPZAR+0.21%USDTRY+0.21%USDNOK+0.19%USDILS+0.16%CHFNOK+0.14%USDJPY-0.13%USDSEK+0.13%USDPLN+0.12%USDCNH-0.12%EURCNH-0.12%EURNOK+0.11%NOKJPY-0.10%EURHKD-0.09%USDDKK+0.08%CHFSEK+0.08%GBPSGD-0.08%EURCHF+0.07%SGDJPY+0.07%EURNZD+0.06%EURGBP+0.05%EURSGD-0.05%NZDSGD+0.05%EURSEK+0.05%NZDCAD-0.05%EURCZK+0.04%EURPLN+0.04%USDCOP-0.04%EURCAD+0.03%USDSGD+0.03%GBPCAD-0.03%CADCHF+0.03%PLNJPY-0.03%NZDCHF-0.02%CHFSGD-0.02%GBPCHF+0.02%GBPNZD+0.02%USDHKD-0.01%EURDKK0.00%UKOIL+0.52%W1-0.51%XNGUSD-0.46%C1-0.41%XPTUSD-0.38%USOIL+0.32%HG1-0.31%S1-0.22%GAUUSD-0.11%XAUUSD-0.11%COTTON+0.08%XAGUSD+0.06%BTCUSD-3.46%ETHUSD+57.77%USDTUSD-0.01%XRPUSD+52.58%SOLUSD+57.55%TRXUSDT+0.77%ZECUSDT-6.58%XMRUSDT-1.65%DOGEUSD+55.95%LINKUSD-3.12%XLMUSD-3.50%BCHUSDT-3.41%LTCUSD+47.50%UNIUSD-2.84%SUIUSD-2.76%TONUSD+59.18%HBARUSDT-4.95%TAOUSDT-2.97%AAVEUSD-3.45%ONDOUSDT-5.16%ICPUSDT-1.57%DOTUSDT-3.63%WLDUSDT-3.57%ARBUSDT-5.49%ATOMUSDT-2.24%INJUSDT-7.58%STXUSDT-2.75%PYTHUSDT-0.96%TIAUSDT-2.82%FETUSDT-4.16%JUPUSDT+0.63%SEIUSDT-4.48%GRTUSDT-3.22%OPUSDT-2.63%IOTAUSDT-2.46%POLUSDT-1.89%WIFUSDT-2.25%AXSUSDT-2.76%EOSUSDT-3.95%IMXUSDT-3.36%FARTCOINUSDT-6.28%GALAUSDT-1.65%DYDXUSDT-2.47%ORDIUSDT-2.25%NOTUSDT+0.86%RONINUSDT-2.92%AAPL+0.64%MSFT+1.07%NVDA+0.64%GOOGL+0.80%AMZN+1.46%SPCX+1.27%TSM+0.81%AVGO+3.64%META+0.81%TSLA+0.74%LLY-2.33%WMT-0.13%AMD+5.31%SKHY-0.11%JPM-1.77%BRK-B-2.07%MU+1.55%V-0.37%JNJ-2.15%XOM-3.97%MA-0.37%ASMLa+1.94%ABBV-2.33%COST-1.21%1398.HK-0.79%0700.HK-5.82%KO-0.71%CVX-4.74%PG-0.83%CSCO+2.18%0939.HK-0.24%ORCL-0.97%3988.HK-0.36%GE+0.52%BAC-1.07%HD-0.40%1816.HK-26.17%0857.HK-2.43%UNH-10.21%1288.HK-1.64%PM-0.85%0005.HK-2.03%NVS-2.46%HSBA.L-2.00%INTC-0.91%MS-1.29%AMAT+0.88%AP2d+2.23%AZN-1.93%TXN-1.16%AUDJPY-1.58%AUDUSD-1.47%EURAUD+0.95%AUDCAD-0.92%AUDCHF-0.90%GBPAUD+0.88%AUDNZD-0.88%NZDJPY-0.72%GBPJPY-0.70%CHFJPY-0.68%CADJPY-0.67%EURJPY-0.65%USDCHF+0.60%NZDUSD-0.59%GBPUSD-0.57%USDCAD+0.57%AUDSGD-0.56%EURUSD-0.52%AUDDKK-0.51%GBPTRY+0.41%AUDNOK-0.40%USDZAR+0.33%GBPHKD+0.32%NZDMXN+0.32%USDMXN+0.32%USDTHB+0.30%GBPMXN-0.28%EURZAR+0.24%GBPZAR+0.21%USDTRY+0.21%USDNOK+0.19%USDILS+0.16%CHFNOK+0.14%USDJPY-0.13%USDSEK+0.13%USDPLN+0.12%USDCNH-0.12%EURCNH-0.12%EURNOK+0.11%NOKJPY-0.10%EURHKD-0.09%USDDKK+0.08%CHFSEK+0.08%GBPSGD-0.08%EURCHF+0.07%SGDJPY+0.07%EURNZD+0.06%EURGBP+0.05%EURSGD-0.05%NZDSGD+0.05%EURSEK+0.05%NZDCAD-0.05%EURCZK+0.04%EURPLN+0.04%USDCOP-0.04%EURCAD+0.03%USDSGD+0.03%GBPCAD-0.03%CADCHF+0.03%PLNJPY-0.03%NZDCHF-0.02%CHFSGD-0.02%GBPCHF+0.02%GBPNZD+0.02%USDHKD-0.01%EURDKK0.00%UKOIL+0.52%W1-0.51%XNGUSD-0.46%C1-0.41%XPTUSD-0.38%USOIL+0.32%HG1-0.31%S1-0.22%GAUUSD-0.11%XAUUSD-0.11%COTTON+0.08%XAGUSD+0.06%BTCUSD-3.46%ETHUSD+57.77%USDTUSD-0.01%XRPUSD+52.58%SOLUSD+57.55%TRXUSDT+0.77%ZECUSDT-6.58%XMRUSDT-1.65%DOGEUSD+55.95%LINKUSD-3.12%XLMUSD-3.50%BCHUSDT-3.41%LTCUSD+47.50%UNIUSD-2.84%SUIUSD-2.76%TONUSD+59.18%HBARUSDT-4.95%TAOUSDT-2.97%AAVEUSD-3.45%ONDOUSDT-5.16%ICPUSDT-1.57%DOTUSDT-3.63%WLDUSDT-3.57%ARBUSDT-5.49%ATOMUSDT-2.24%INJUSDT-7.58%STXUSDT-2.75%PYTHUSDT-0.96%TIAUSDT-2.82%FETUSDT-4.16%JUPUSDT+0.63%SEIUSDT-4.48%GRTUSDT-3.22%OPUSDT-2.63%IOTAUSDT-2.46%POLUSDT-1.89%WIFUSDT-2.25%AXSUSDT-2.76%EOSUSDT-3.95%IMXUSDT-3.36%FARTCOINUSDT-6.28%GALAUSDT-1.65%DYDXUSDT-2.47%ORDIUSDT-2.25%NOTUSDT+0.86%RONINUSDT-2.92%
DT

Denali Therapeutics Inc. (DNLI)

NASDAQ • Healthcare

$18.39
+$0.39 (+2.2%)
Market closed

Last close at November 18, 2026 at 21:00 UTC

Open$18.02
Day Range$17.92 - $18.58
Avg. Volume (3M)1.5M
Market Cap$2.9B
52 Week Range
$15.34$27.3

Metrics Over Time

Where the Money Goes

Q3 2026
Revenueeverything earned$17.7M100%
Gross Profitminus cost of goods$17.5M99%
Net Incomeminus taxes and the rest$70.1M394%

Fundamentals & Financials

Revenue (TTM)
$21.3M
Net Income (TTM)
-$314.4M
EPS (TTM)
-$1.73
ROA (TTM)
-25.03%
Current Ratio
6.21

TTM is calculated as the sum of the four most recently completed quarters. This is a standard approach when monthly or real-time data is not available.

Earnings

+5.5%Q2 2026-$0.69
-32.5%Q3 2026-$0.68
+236.6%Q4 2026$0.37

% — EPS deviation from the forecast (beat / miss); quarters without a forecast show the reported EPS

Latest report — Q4 2026
Beat +236.6%

Revenue fell year over year to about $17.8 million in Denali Therapeutics’ third fiscal quarter of 2026, which it reported on November 3, 2026, as the clinical-stage biotech continues advancing programs across neurodegenerative and related diseases including Parkinson’s disease and ALS as well as Hunter syndrome. Profitability remained negative, with operating income of roughly -$126.8 million under GAAP, reflecting the company’s ongoing investment profile as it develops candidates such as BIIB122/DNL151, DNL310, DNL343, and other earlier-stage programs. Consensus for the next period calls for EPS of -$0.64 on revenue of $27.5 million.

View full earnings history

About Denali Therapeutics Inc.

Denali Therapeutics Inc. is a U.S.-focused biotechnology company listed on NASDAQ as DNLI that develops drug candidates for neurodegenerative and related diseases. In qualitative terms, it is a clinical-stage healthcare business built around advancing targeted therapies, with programs that span Parkinson's disease, ALS, Hunter syndrome, multiple sclerosis, Alzheimer's disease, and cutaneous lupus erythematosus.

Name
Denali Therapeutics Inc.
CEO
Ryan J. Watts
Industry
Healthcare
Year Founded
2013
Employees
503

Today's Snapshot

AI-generated

DNLI closed 2.2% higher on heavier trading than usual. Denali Therapeutics launched AVLAYAH, a new treatment.

Trading Volume

Above 10d avg 1.4M

2M

vs S&P 500 Today

Outperforming Market

+2.48%

Updated: November 18, 2026 at 21:22 UTC

Technical Indicators

1 Buy1 Neutral6 Sell
DNLI sits beneath its short- and long-term averages, with the current price near 18.40 showing weakness relative to the 200-day level. Momentum and MACD are modestly negative while RSI remains below neutral, suggesting tepid downward pressure; ADX near 20 points to a lack of strong trend conviction. ATR is relatively elevated as a percentage, and the sizable negative OBV reading paradoxically signals recent accumulation despite price softness; the classic pivot around 17.81 is just below current levels. Technical takeaway: Strong Sell — price weakness and negative momentum amid mixed volume signals.
All signals
  • EMA (5 indicators)$18.86 - $20.62
    Sell
  • RSI (14)42.65
    Neutral
  • Stochastic %K (14, 3, 3)13.68
    Buy
  • MACD Level (12, 26)-0.29
    Sell
Stay Ahead of the Market

Get premium market insights delivered directly to your inbox.